Prognostic and clinicopathological utility of PD-L2 expression in patients with digestive system cancers: A meta-analysis
•PD-L2, oneoftwoligandsfor PD-1, has already been detected in various cancers.•High PD-L2 overexpression indicates poor prognosis in digestive system cancers.•High PD-L2 overexpression is associated with lymphatic metastasis, tumor metastasis and histopathological stage. Programmed death ligand-2 (P...
Gespeichert in:
| Veröffentlicht in: | International immunopharmacology 2020-11, Vol.88, p.106946-106946, Article 106946 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 106946 |
|---|---|
| container_issue | |
| container_start_page | 106946 |
| container_title | International immunopharmacology |
| container_volume | 88 |
| creator | Lin, Xiaochun Lin, Kunpeng Lin, Chunxuan Wang, Jiakang Tang, Yunqiang |
| description | •PD-L2, oneoftwoligandsfor PD-1, has already been detected in various cancers.•High PD-L2 overexpression indicates poor prognosis in digestive system cancers.•High PD-L2 overexpression is associated with lymphatic metastasis, tumor metastasis and histopathological stage.
Programmed death ligand-2 (PD-L2)has been detected in various cancers. However, its prognostic value in digestive system cancers (DSCs) remains unclear. Accordingly, this meta-analysis investigated the prognostic and clinicopathological utility of PD-L2 in patients with DSCs.
We systematically searched PubMed, EMBASE, Web of Science, ClinicalTrials.gov., Scopus, and Cochrane Library databases for eligible studies up to April 30, 2020. The hazard ratio (HR), odds ratio (OR), and corresponding 95% confidence interval (CI) of the outcomes were calculated.
Twenty two studies with 4886 patients were included in this meta-analysis. The pooled results showed that PD-L2 overexpression was significantly associated with poor overall survival (OS) (HR 1.470, 95% CI: 1.252–1.728, p |
| doi_str_mv | 10.1016/j.intimp.2020.106946 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2460762299</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576920318798</els_id><sourcerecordid>2478821723</sourcerecordid><originalsourceid>FETCH-LOGICAL-c367t-5572e1cf498080ea08241a08cb50c2e9a1b8400c5b2160b1705e11fe47bf173b3</originalsourceid><addsrcrecordid>eNp9kT1v3DAMho0gBfLR_oMMArJk8VXS2ZLdoUCQ9As4oBnaWZB19IUHW3JFXVr_-8pwpwxdSIJ4-ILkWxQ3gm8EF-r9cYM-4ThtJJdLS7WVOisuRaObUmhen-e6VrqstWoviiuiI-e5X4nLYn6K4eADJXTM-j1zA3p0YbLpOQzhgM4O7JRwwDSz0LOnx3InGfyZIhBh8Aw9yyyCT8R-Y3pmezxAVnsBRjMlGJmz3kGkD-yejZBsab0dZkJ6W7zp7UDw7l--Ln5-_vTj4Wu5-_7l28P9rnRbpVNZ11qCcH3VNrzhYHkjK5Gj62ruJLRWdE3Fuas7KRTvlnNBiB4q3fVCb7vtdXG36k4x_Drl3cyI5GAYrIdwIiMrxbWSsm0zevsKPYZTzPsulG4aKbTcZqpaKRcDUYTeTBFHG2cjuFn8MEez-mEWP8zqRx77uI5BPvYFIRpy-W8O9hjBJbMP-H-Bv2fwlko</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2478821723</pqid></control><display><type>article</type><title>Prognostic and clinicopathological utility of PD-L2 expression in patients with digestive system cancers: A meta-analysis</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Lin, Xiaochun ; Lin, Kunpeng ; Lin, Chunxuan ; Wang, Jiakang ; Tang, Yunqiang</creator><creatorcontrib>Lin, Xiaochun ; Lin, Kunpeng ; Lin, Chunxuan ; Wang, Jiakang ; Tang, Yunqiang</creatorcontrib><description>•PD-L2, oneoftwoligandsfor PD-1, has already been detected in various cancers.•High PD-L2 overexpression indicates poor prognosis in digestive system cancers.•High PD-L2 overexpression is associated with lymphatic metastasis, tumor metastasis and histopathological stage.
Programmed death ligand-2 (PD-L2)has been detected in various cancers. However, its prognostic value in digestive system cancers (DSCs) remains unclear. Accordingly, this meta-analysis investigated the prognostic and clinicopathological utility of PD-L2 in patients with DSCs.
We systematically searched PubMed, EMBASE, Web of Science, ClinicalTrials.gov., Scopus, and Cochrane Library databases for eligible studies up to April 30, 2020. The hazard ratio (HR), odds ratio (OR), and corresponding 95% confidence interval (CI) of the outcomes were calculated.
Twenty two studies with 4886 patients were included in this meta-analysis. The pooled results showed that PD-L2 overexpression was significantly associated with poor overall survival (OS) (HR 1.470, 95% CI: 1.252–1.728, p < 0.001) and worse disease-free survival (DFS) (HR1.598, 95% CI: 1.398–1.826, p < 0.001). Subgroup analysis revealed that elevated PD-L2 was a significant prognostic indicator of worse OS in hepatocellular carcinoma (HR 1.703, 95% CI: 1.456–1.991, p < 0.001) and colorectal cancer (HR 3.811, 95% CI: 1.718–8.454, p = 0.001). Concerning clinicopathologic factors, PD-L2 overexpression was associated with lymphatic metastasis (OR 1.394., 95% CI: 1.101–1.764, p = 0.006), tumor metastasis (OR 1.599, 95% CI: 1.072–2.383, p = 0.021), and the histopathological stage (OR 0.704, 95% CI: 0.566–0.875, p = 0.002).
PD-L2 overexpression in DSCs after surgery might predict a poor prognosis, especially in hepatocellular carcinoma and colorectal cancer. Larger patient cohorts are needed to validate its prognostic role.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2020.106946</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Cancer ; Colorectal cancer ; Colorectal carcinoma ; Confidence intervals ; Digestive system ; Digestive system cancers ; Hepatocellular carcinoma ; Liver cancer ; Medical prognosis ; Meta-analysis ; Metastases ; Metastasis ; Patients ; PD-L2 ; Physical examinations ; Prognosis ; Subgroups ; Surgery ; Survival</subject><ispartof>International immunopharmacology, 2020-11, Vol.88, p.106946-106946, Article 106946</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright Elsevier BV Nov 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c367t-5572e1cf498080ea08241a08cb50c2e9a1b8400c5b2160b1705e11fe47bf173b3</citedby><cites>FETCH-LOGICAL-c367t-5572e1cf498080ea08241a08cb50c2e9a1b8400c5b2160b1705e11fe47bf173b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2020.106946$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>Lin, Xiaochun</creatorcontrib><creatorcontrib>Lin, Kunpeng</creatorcontrib><creatorcontrib>Lin, Chunxuan</creatorcontrib><creatorcontrib>Wang, Jiakang</creatorcontrib><creatorcontrib>Tang, Yunqiang</creatorcontrib><title>Prognostic and clinicopathological utility of PD-L2 expression in patients with digestive system cancers: A meta-analysis</title><title>International immunopharmacology</title><description>•PD-L2, oneoftwoligandsfor PD-1, has already been detected in various cancers.•High PD-L2 overexpression indicates poor prognosis in digestive system cancers.•High PD-L2 overexpression is associated with lymphatic metastasis, tumor metastasis and histopathological stage.
Programmed death ligand-2 (PD-L2)has been detected in various cancers. However, its prognostic value in digestive system cancers (DSCs) remains unclear. Accordingly, this meta-analysis investigated the prognostic and clinicopathological utility of PD-L2 in patients with DSCs.
We systematically searched PubMed, EMBASE, Web of Science, ClinicalTrials.gov., Scopus, and Cochrane Library databases for eligible studies up to April 30, 2020. The hazard ratio (HR), odds ratio (OR), and corresponding 95% confidence interval (CI) of the outcomes were calculated.
Twenty two studies with 4886 patients were included in this meta-analysis. The pooled results showed that PD-L2 overexpression was significantly associated with poor overall survival (OS) (HR 1.470, 95% CI: 1.252–1.728, p < 0.001) and worse disease-free survival (DFS) (HR1.598, 95% CI: 1.398–1.826, p < 0.001). Subgroup analysis revealed that elevated PD-L2 was a significant prognostic indicator of worse OS in hepatocellular carcinoma (HR 1.703, 95% CI: 1.456–1.991, p < 0.001) and colorectal cancer (HR 3.811, 95% CI: 1.718–8.454, p = 0.001). Concerning clinicopathologic factors, PD-L2 overexpression was associated with lymphatic metastasis (OR 1.394., 95% CI: 1.101–1.764, p = 0.006), tumor metastasis (OR 1.599, 95% CI: 1.072–2.383, p = 0.021), and the histopathological stage (OR 0.704, 95% CI: 0.566–0.875, p = 0.002).
PD-L2 overexpression in DSCs after surgery might predict a poor prognosis, especially in hepatocellular carcinoma and colorectal cancer. Larger patient cohorts are needed to validate its prognostic role.</description><subject>Cancer</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Confidence intervals</subject><subject>Digestive system</subject><subject>Digestive system cancers</subject><subject>Hepatocellular carcinoma</subject><subject>Liver cancer</subject><subject>Medical prognosis</subject><subject>Meta-analysis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Patients</subject><subject>PD-L2</subject><subject>Physical examinations</subject><subject>Prognosis</subject><subject>Subgroups</subject><subject>Surgery</subject><subject>Survival</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kT1v3DAMho0gBfLR_oMMArJk8VXS2ZLdoUCQ9As4oBnaWZB19IUHW3JFXVr_-8pwpwxdSIJ4-ILkWxQ3gm8EF-r9cYM-4ThtJJdLS7WVOisuRaObUmhen-e6VrqstWoviiuiI-e5X4nLYn6K4eADJXTM-j1zA3p0YbLpOQzhgM4O7JRwwDSz0LOnx3InGfyZIhBh8Aw9yyyCT8R-Y3pmezxAVnsBRjMlGJmz3kGkD-yejZBsab0dZkJ6W7zp7UDw7l--Ln5-_vTj4Wu5-_7l28P9rnRbpVNZ11qCcH3VNrzhYHkjK5Gj62ruJLRWdE3Fuas7KRTvlnNBiB4q3fVCb7vtdXG36k4x_Drl3cyI5GAYrIdwIiMrxbWSsm0zevsKPYZTzPsulG4aKbTcZqpaKRcDUYTeTBFHG2cjuFn8MEez-mEWP8zqRx77uI5BPvYFIRpy-W8O9hjBJbMP-H-Bv2fwlko</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Lin, Xiaochun</creator><creator>Lin, Kunpeng</creator><creator>Lin, Chunxuan</creator><creator>Wang, Jiakang</creator><creator>Tang, Yunqiang</creator><general>Elsevier B.V</general><general>Elsevier BV</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>202011</creationdate><title>Prognostic and clinicopathological utility of PD-L2 expression in patients with digestive system cancers: A meta-analysis</title><author>Lin, Xiaochun ; Lin, Kunpeng ; Lin, Chunxuan ; Wang, Jiakang ; Tang, Yunqiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c367t-5572e1cf498080ea08241a08cb50c2e9a1b8400c5b2160b1705e11fe47bf173b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cancer</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Confidence intervals</topic><topic>Digestive system</topic><topic>Digestive system cancers</topic><topic>Hepatocellular carcinoma</topic><topic>Liver cancer</topic><topic>Medical prognosis</topic><topic>Meta-analysis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Patients</topic><topic>PD-L2</topic><topic>Physical examinations</topic><topic>Prognosis</topic><topic>Subgroups</topic><topic>Surgery</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, Xiaochun</creatorcontrib><creatorcontrib>Lin, Kunpeng</creatorcontrib><creatorcontrib>Lin, Chunxuan</creatorcontrib><creatorcontrib>Wang, Jiakang</creatorcontrib><creatorcontrib>Tang, Yunqiang</creatorcontrib><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Xiaochun</au><au>Lin, Kunpeng</au><au>Lin, Chunxuan</au><au>Wang, Jiakang</au><au>Tang, Yunqiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic and clinicopathological utility of PD-L2 expression in patients with digestive system cancers: A meta-analysis</atitle><jtitle>International immunopharmacology</jtitle><date>2020-11</date><risdate>2020</risdate><volume>88</volume><spage>106946</spage><epage>106946</epage><pages>106946-106946</pages><artnum>106946</artnum><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>•PD-L2, oneoftwoligandsfor PD-1, has already been detected in various cancers.•High PD-L2 overexpression indicates poor prognosis in digestive system cancers.•High PD-L2 overexpression is associated with lymphatic metastasis, tumor metastasis and histopathological stage.
Programmed death ligand-2 (PD-L2)has been detected in various cancers. However, its prognostic value in digestive system cancers (DSCs) remains unclear. Accordingly, this meta-analysis investigated the prognostic and clinicopathological utility of PD-L2 in patients with DSCs.
We systematically searched PubMed, EMBASE, Web of Science, ClinicalTrials.gov., Scopus, and Cochrane Library databases for eligible studies up to April 30, 2020. The hazard ratio (HR), odds ratio (OR), and corresponding 95% confidence interval (CI) of the outcomes were calculated.
Twenty two studies with 4886 patients were included in this meta-analysis. The pooled results showed that PD-L2 overexpression was significantly associated with poor overall survival (OS) (HR 1.470, 95% CI: 1.252–1.728, p < 0.001) and worse disease-free survival (DFS) (HR1.598, 95% CI: 1.398–1.826, p < 0.001). Subgroup analysis revealed that elevated PD-L2 was a significant prognostic indicator of worse OS in hepatocellular carcinoma (HR 1.703, 95% CI: 1.456–1.991, p < 0.001) and colorectal cancer (HR 3.811, 95% CI: 1.718–8.454, p = 0.001). Concerning clinicopathologic factors, PD-L2 overexpression was associated with lymphatic metastasis (OR 1.394., 95% CI: 1.101–1.764, p = 0.006), tumor metastasis (OR 1.599, 95% CI: 1.072–2.383, p = 0.021), and the histopathological stage (OR 0.704, 95% CI: 0.566–0.875, p = 0.002).
PD-L2 overexpression in DSCs after surgery might predict a poor prognosis, especially in hepatocellular carcinoma and colorectal cancer. Larger patient cohorts are needed to validate its prognostic role.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><doi>10.1016/j.intimp.2020.106946</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1567-5769 |
| ispartof | International immunopharmacology, 2020-11, Vol.88, p.106946-106946, Article 106946 |
| issn | 1567-5769 1878-1705 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2460762299 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | Cancer Colorectal cancer Colorectal carcinoma Confidence intervals Digestive system Digestive system cancers Hepatocellular carcinoma Liver cancer Medical prognosis Meta-analysis Metastases Metastasis Patients PD-L2 Physical examinations Prognosis Subgroups Surgery Survival |
| title | Prognostic and clinicopathological utility of PD-L2 expression in patients with digestive system cancers: A meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T12%3A45%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20and%20clinicopathological%20utility%20of%20PD-L2%20expression%20in%20patients%20with%20digestive%20system%20cancers:%20A%20meta-analysis&rft.jtitle=International%20immunopharmacology&rft.au=Lin,%20Xiaochun&rft.date=2020-11&rft.volume=88&rft.spage=106946&rft.epage=106946&rft.pages=106946-106946&rft.artnum=106946&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2020.106946&rft_dat=%3Cproquest_cross%3E2478821723%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2478821723&rft_id=info:pmid/&rft_els_id=S1567576920318798&rfr_iscdi=true |